메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국보건경제정책학회 보건경제와 정책연구 보건경제와 정책연구 제17권 제4호
발행연도
2011.1
수록면
23 - 42 (20page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
General expectation on generics is that they will bring about substantial savings of drug expenditures by substituting their expensive branded counterparts. So far in Korea, not much empirical studies done in this area. Recent Korean policy intervention on generics is focusing on the price cut under the assumption that lowering price would directly be linked to curtailment of drug expenditures. This study aims to investigate the savings on drug spendings with the introduction of generics. NHI claims data of 6 substances - Pioglitazone, Voglibose, Metformin, Glimepiride, Tolterodine, Clopidogrel - are used to examine the expected impact of generics. Drug spendings of 2009 were compared with those of 2006. Each substance in the study is considered to have experienced strong generic adoption since 2006. The results are the followings. Generic introduction contributed to about 70%~216% increase in drug expenditures. The quantity effect was positive for all substances with increasing rate of 1.13~3.90. This implies that generic introduction created new market for survival rather than jumped into the original market to compete with. Drug mix effect of generic introduction in all substances in the range of 0.83~0.97, impling that original drugs had been slightly substituted for generics during the period under study. A salient feature of this study is that after the generic introduction, use of generics has increased along with their original counterpart. In other words, the volume of original drugs hasn't been decreased but increased instead. The only exception was the case of Pioglitazone. In conclusion, Even when the generics were actively introduced, we could not witness the fall in drug spendings. For drug spendings to be reduced, the policy such as reference pricing system could be considered as an option for the future.

목차

등록된 정보가 없습니다.

참고문헌 (13)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0